UPN | Age | Sex | Weight | BSA | Bu Dose | Risk Category1-150 |
---|---|---|---|---|---|---|
kg | m2 | mg/kg | ||||
29 | 4 | F | 13.5 | 0.65 | 28.4 | II |
95 | 9 | F | 23 | 0.9 | 23.6 | III |
98 | 2 | M | 15 | 0.6 | 16 | II |
99 | 5 | M | 15 | 0.65 | 25.6 | III |
100 | 10 | M | 16 | 0.73 | 16 | III |
103 | 5.5 | M | 18 | 0.73 | 16 | III |
104 | 4 | M | 14 | 0.60 | 25.1 | III |
105 | 2.5 | F | 10.4 | 0.50 | 27.7 | II |
106 | 10 | F | 28 | 1.00 | 16 | III |
109 | 13 | F | 33 | 1.09 | 19.9 | III |
110 | 13 | F | 23.8 | 0.88 | 22 | III |
111 | 5 | M | 14.5 | 0.7 | 28.7 | III |
121 | 2.5 | M | 11.2 | 0.51 | 25.7 | I |
122 | 4.5 | M | 14.2 | 0.67 | 28.2 | I |
123 | 2.5 | M | 11.1 | 0.55 | 29 | II |
124 | 4.5 | M | 14 | 0.60 | 16 | II |
125 | 2 | F | 11.3 | 0.52 | 27 | I |
128 | 12 | M | 25 | 0.96 | 16 | III |
131 | 5.5 | F | 15 | 0.70 | 16 | III |
133 | 13 | M | 29 | 1.05 | 16 | III |
134 | 3 | M | 12 | 0.74 | 16 | II |
136 | 7 | F | 20 | 0.80 | 16 | III |
139 | 5 | F | 20 | 0.84 | 16 | II |
140 | 11 | M | 25.3 | 0.95 | 22.7 | III |
142 | 10 | M | 18 | 0.80 | 16 | III |
143 | 7 | M | 20 | 0.82 | 24 | III |
144 | 14 | M | 32 | 1.20 | 16 | III |
151 | 5.5 | M | 15 | 0.62 | 24.5 | II |
157 | 6.5 | F | 19 | 0.84 | 26 | III |
159 | 15 | F | 26 | 1.12 | 14 | III |
160 | 13 | M | 30 | 1.10 | 16 | III |
161 | 3.3 | M | 11 | 0.52 | 29 | II |
162 | 11 | F | 34 | 1.10 | 16 | III |
163 | 11 | M | 20 | 0.80 | 16 | III |
165 | 5 | F | 20 | 0.80 | 16 | III |
166 | 6 | F | 11 | 0.50 | 16 | II |
167 | 12 | M | 26.9 | 1.00 | 22.6 | III |
168 | 6 | F | 18 | 0.73 | 24.4 | II |
170 | 5 | M | 17 | 0.66 | 16 | III |
UPN, unique patient number; Bu, busulfan.
↵1-150 Risk category as per Lucarelli et al. (1990).